Ceftibuten--in-vitro activity against respiratory pathogens, beta-lactamase stability and mechanism of action.
The in-vitro activity of ceftibuten against respiratory pathogenic bacteria was studied and compared with that of other oral beta-lactam agents. Ceftibuten displayed high activity against Haemophilus influenzae and Branhamella catarrhalis. There was reduced activity against Streptococcus pneumoniae (MIC90 16 mg/l). The protein binding of ceftibuten was 77% and the primary target site PBP 3. A high degree of stability to beta-lactamase hydrolysis was observed.
Wise
R
R
Department of Medical Microbiology, Dudley Road Hospital, Birmingham, UK.
Andrews
J M
JM
Ashby
J P
JP
Thornber
D
D
D000900:Anti-Bacterial Agents / Q000494:pharmacology; D000077722:Ceftibuten; D002511:Cephalosporins / Q000494:pharmacology*; D004352:Drug Resistance, Microbial; D004795:Enzyme Stability / Q000187:drug effects; D006193:Haemophilus influenzae / Q000187:drug effects*; D001936:Moraxella catarrhalis / Q000187:drug effects*; D010403:Penicillin Resistance; D013296:Streptococcus pneumoniae / Q000187:drug effects*; D001618:beta-Lactamases / Q000378:metabolism / Q000494:pharmacology*
D000900:Anti-Bacterial Agents; D002511:Cephalosporins; D001618:beta-Lactamases; D000077722:Ceftibuten